Considerable progress has been made in predicting and managing immunogenicity, or the propensity of a therapeutic protein product to generate immune responses to itself. This meeting will discuss how immunogenicity can be predicted and controlled. Delegates will discuss next generation biologics, novel assays and ways to humanise biotherapeutics.
